2029 Biopharma Pharma Sales 
Clarivate
JANUARY 8, 2024
Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. Granted U.S.
Pharmaceutical Technology
APRIL 4, 2023
According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 billion in 2029. The biopharma aims to start the study as soon as the IND is cleared by the FDA. Tagrisso was approved for use as a first-line treatment for metastatic NSCLC with EGFR mutation in April 2018.
Expert insights. Personalized for you.
59 
Let's personalize your content